Kailera Therapeutics is trading at $11.53, up 7.06%, with no company-specific announcement or confirmed catalyst for the after-hours rise identified in available reports. - Kailera's latest listed release was October 1; its Phase 3 enrollment announcement was published September 30, with topline data expected in mid-2028, and does not establish a cause for this move. - Broader markets showed mixed, modest index moves October 13, offering no clear same-direction explanation. Shares had closed regular trading at $10.77, down 4.94%.